SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024. Q3 2024 Financial Results Conference Call Management will host a conference call and live audio webcast to discuss these results and provide a corpo ...

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.Iovance Biotherapeutics (IOVA 7.54%) is going to finish the week strong on the stock market if its Thursday performance is any indication. Investors boosted the company's share price by almost 8%, following the initiation of coverage by an analyst who's bullish on its future. With that rise, Iovance easily eclipsed the S&P 500 index's 0.2% increase.Vast potential with melanoma drugThe analyst launching his Iovance ...

The biotech is making important breakthroughs, but is that enough? These are exciting times to be an Iovance Biotherapeutics (IOVA) shareholder. The biotech has made encouraging clinical and regulatory progress in the past year. Its most important product is helping it generate strong revenue growth, and although it has been a bit of a wild and volatile ride, its shares have performed much better than the broader market over the trailing 12-month period. It might be worth investing in the stock if the compa ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial. In my previous Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) article, I discussed the company's preparations for the FDA's impending verdict on lifileucel, their tumor-infiltrating lymphocyte ("TIL") therapy for advanced melanoma. I was expecting the ti ...

This biotech's growth story is going to start moving faster, and soon. Now's a great time to build up a position in Iovance Biotherapeutics (IOVA -1.28%) with the aim of holding on to its shares for the next few years. Between the recent launch of its innovative cell therapy, strong progress in building up its network of clinics, and a financial situation that looks well-matched to its substantial needs in the near term, this is a biotech that's as well-positioned as stocks in this very risky category tend ...

There's plenty of upside with this stock, but it might take a while to realize. Iovance Biotherapeutics (IOVA 9.30%) is a hot biotech stock for a reason: It's almost certainly going to be growing its top line at a snappy pace over the next few years, and there's no other therapy that's quite like the one it recently started to commercialize. But, like most of the companies in its group, there are a lot of caveats and tidbits of industry knowledge that you'll need to appreciate before you can feel confident ...

Investors should brace for dilution. Iovance Biotherapeutics (IOVA -0.19%) investors received great news earlier this year when the U.S. Food and Drug Administration granted it accelerated approval for the company's cell therapy treatment for advanced melanoma, Amtagvi. It gives the business a crucial product to build its operations around. Growth investors were initially bullish on the news, but in recent months, the stock has started to struggle. While there is a lot more optimism surrounding the company, ...

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. It's been a wild roller-coaster ride for Iovance Biotherapeutics (IOVA 0.25%). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since recovered and at recent prices was up 47% for the year. Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near ...

It could demonstrate a few capabilities that no other biotech has as of yet. It's an exciting time to be a shareholder of Iovance Biotherapeutics (IOVA 6.50%). Thanks to the recent launch of its flagship medicine, it's now accruing sales revenue for the first time ever, and there's plenty of growth on the way. Still, the upstart biotech has to answer a couple of prickly questions about how viable its therapy will be to produce and distribute over the long term. There's a risk that it won't be able to do so. ...

Hinterhaus Productions Iovance's Strong Q2 Reinforces Case for Amtagvi's Success Following its accelerated approval in melanoma earlier this year, Iovance's (NASDAQ:IOVA) Amtagvi (lifileucel) became the first T cell therapy to be approved for a solid tumor. The achievement came after decades of research into tumor-infiltrating lymphocytes, or TIL therapy. In my previous article on Iovance, I acknowledged that, while Amtagvi was a significant step forward, it faces challenges due to its high cost, intensive ...